{"id":"NCT02607280","sponsor":"Daiichi Sankyo Co., Ltd.","briefTitle":"DS-5565 Phase III Study for Renal Impairment in Japanese Subjects","officialTitle":"A JAPANESE, PHASE 3, OPEN-LABEL, 14-WEEK STUDY OF DS-5565 IN PATIENTS WITH PAIN ASSOCIATED WITH DIABETIC PERIPHERAL NEUROPATHY WITH RENAL IMPAIRMENT OR POST-HERPETIC NEURALGIA WITH RENAL IMPAIRMENT","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12","primaryCompletion":"2017-03","completion":"2017-03","firstPosted":"2015-11-18","resultsPosted":"2020-10-26","lastUpdate":"2021-05-13"},"enrollment":35,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Peripheral Neuropathic Pain","Post-herpetic Neuralgia"],"interventions":[{"type":"DRUG","name":"DS-5565","otherNames":["mirogabalin"]}],"arms":[{"label":"DS-5565 group","type":"EXPERIMENTAL"}],"summary":"Investigate the safety and efficacy of DS-5565 in Japanese subjects with Diabetic Peripheral Neuropathic Pain (DPNP) with renal impairment or Post-Herpetic Neuralgia (PHN) with renal impairment.","primaryOutcome":{"measure":"Change From Baseline in Average Daily Pain Score (ADPS) at Each Week","timeFrame":"Baseline to Week 14","effectByArm":[{"arm":"Moderate Renal Impairment","deltaMin":-0.14,"sd":0.68},{"arm":"Severe Renal Impairment","deltaMin":-0.2,"sd":0.217}],"pValues":[{"comp":"OG000","p":null},{"comp":"OG001","p":null}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":1,"countries":["Japan"]},"refs":{"pmids":["32765056"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":30},"commonTop":["Nasopharyngitis","Somnolence","Oedema peripheral","Dizziness","Sensory disturbance"]}}